Skip to main content
. Author manuscript; available in PMC: 2021 Jul 9.
Published in final edited form as: Leuk Lymphoma. 2020 Aug 27;61(14):3468–3475. doi: 10.1080/10428194.2020.1811272

Figure 2.

Figure 2

Kaplan Meier survival estimate comparing the kinetics of MRD across TP1 and TP2. (Cutoff for MRD positivity is ≥ 0.01%). Patients who were persistently MRD positive at TP1 and TP2 had a poor OS, RFS and EFS when compared to the patients who achieved MRD negativity either at TP1 or at TP2. (p value for the entire cohort is shown here while p value between the individual subgroups in this comparison is shown in Table 3).